{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:16:16Z","timestamp":1761884176539,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.reumae.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T16:15:30Z","timestamp":1680279330000},"page":"215-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rheumatological adverse events secondary to immune checkpoint inhibitors"],"prefix":"10.1016","volume":"19","author":[{"given":"Mar\u00eda Cecilia","family":"Garbarino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osvaldo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Zylberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2023.03.001_bib0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khanlil","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0010","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reumae.2023.03.001_bib0015","first-page":"925","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"162","author":"Haslam","year":"2019","journal-title":"JAMA Net Open."},{"key":"10.1016\/j.reumae.2023.03.001_bib0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/annrheumdis-2017-212061","article-title":"The evolving role of the rheumatologist in the management of immune related adverse events (irAEs) caused by cancer immunotherapy","volume":"77","author":"Calabrese","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2023.03.001_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2016-209782","article-title":"Check point immunotherapy: good for cancer therapy, bad for rheumatic diseases","volume":"76","author":"Calabrese","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2023.03.001_bib0030","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s10067-020-05420-w","article-title":"Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Is time for a paradigm shift?","volume":"40","author":"Chatzdionysiou","year":"2021","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0035","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3899\/jrheum.190084","article-title":"Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist","volume":"47","author":"Jammal","year":"2020","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reumae.2023.03.001_bib0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ctrv.2018.04.004","article-title":"Evolution of the checkpoint inhibitors for the treatment of metastasic cancers: current status and future perspectives","volume":"66","author":"Taieba","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.reumae.2023.03.001_bib0050","first-page":"208","article-title":"Reacciones adversas a medicamentos inhibidores del punto de control inmunitario","volume":"81","author":"Manzano","year":"2021","journal-title":"Medicina."},{"key":"10.1016\/j.reumae.2023.03.001_bib0055","first-page":"54","article-title":"Inmunoterapia en c\u00e1ncer. Lo que debe saber el reumatologo","volume":"2","author":"Rivero","year":"2017","journal-title":"Autoinmunidad."},{"key":"10.1016\/j.reumae.2023.03.001_bib0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2023.03.001_bib0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD 1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int J Rheum Dis."},{"key":"10.1016\/j.reumae.2023.03.001_bib0070","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0075","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.reumae.2023.03.001_bib0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new onset arthritis after checkpoint inhibitors therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open."},{"key":"10.1016\/j.reumae.2023.03.001_bib0085","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2017","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.reumae.2023.03.001_bib0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer. Clinical aspects and relationship with response: a single center prospective cohort study","volume":"77","author":"Kostine","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2023.03.001_bib0095","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitors induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.reumae.2023.03.001_bib0100","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2017.10.018","article-title":"Rheumatologic symptoms in oncologic patients on PD 1 inhibitors","volume":"47","author":"Kuswanto","year":"2018","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.reumae.2023.03.001_bib0105","first-page":"43","article-title":"EULAR points to consider for the diagnosis and management of the rheumatic immune-related adverse due to cancer immunotherapy with checkpoint inhibitors","volume":"76","author":"Kostine","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2023.03.001_bib0110","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.reumae.2023.03.001_bib0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","article-title":"Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastasic melanoma","volume":"42","author":"Chan","year":"2015","journal-title":"J Immunother."},{"key":"10.1016\/j.reumae.2023.03.001_bib0120","first-page":"301","article-title":"Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibitors: a case series","volume":"62","author":"Albayda","year":"2019","journal-title":"ACR Open Rheum."},{"key":"10.1016\/j.reumae.2023.03.001_bib0125","first-page":"3389","article-title":"Rheumatic manifestations in patients treated with immune checkpoint inhibitors","volume":"23","author":"Konstantinos","year":"2020","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.reumae.2023.03.001_bib0130","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint inhibitor associated arthritis: a systematic review of case reports and case series","volume":"27","author":"Ghosh","year":"2021","journal-title":"J Clin Rheumatol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0135","first-page":"345","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor induced inflammatory arthritis","volume":"79","author":"Cappelli","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reumae.2023.03.001_bib0140","first-page":"165","article-title":"Paraneoplasic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report","volume":"34","author":"Shibata","year":"2019","journal-title":"J Med Case Rep."},{"key":"10.1016\/j.reumae.2023.03.001_bib0145","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor induce musculoskeletal manifestations, myofascitis is the prominent image finding","volume":"59","author":"Daoussis","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reumae.2023.03.001_bib0150","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD1 inhibitors: fascitis with myositis syndrome as a new complication of immunotherapy","volume":"64","author":"Narvaez","year":"2018","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.reumae.2023.03.001_bib0155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.reumae.2023.03.001_bib0160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Modering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.reumae.2023.03.001_bib0165","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jaad.2018.07.051","article-title":"Immune checkpoint inhibitors and the development of granulomatosis reactions","volume":"81","author":"Cornejo","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","article-title":"Nivolumab related cutaneous sarcoidosis in a patient with lung adenocarcinoma","volume":"3","author":"Birnbaum","year":"2017","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.reumae.2023.03.001_bib0175","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000491599","article-title":"Neurosarcoidosis following immune checkpoint inhibitor","volume":"11","author":"Dunn-Pirio","year":"2018","journal-title":"Case Rep Oncol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0180","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"176","author":"Montaudie","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0185","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3389\/fimmu.2019.01638","article-title":"Decreased Expression of negative immune checkpoint VISTA by CD4+ T cells facilitates T helper 1, T helper 17, and T follicular helper lineage differentiation in GCA","volume":"10","author":"Cadena","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0190","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors. A systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaut.2019.102333","article-title":"Immune checkpoint molecules, possible future therapeutic implications in autoimmune diseases","volume":"104","author":"Huang","year":"2019","journal-title":"J Autoimmun."},{"key":"10.1016\/j.reumae.2023.03.001_bib0200","first-page":"2434","article-title":"Influence of CTLA 4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren syndrome","volume":"62","author":"Downey Doyle","year":"2016","journal-title":"Arthritis Rheum."},{"issue":"Suppl 7","key":"10.1016\/j.reumae.2023.03.001_bib0205","doi-asserted-by":"crossref","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel Wahab","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reumae.2023.03.001_bib0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0215","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3390\/cells8101213","article-title":"The role of immune checkpoint receptors in regulating immune reactivity in Lupus","volume":"78","author":"Lu","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.reumae.2023.03.001_bib0220","first-page":"78","article-title":"Checkpoint inhibitor associated immune arthritis","volume":"41","author":"Arnaud","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2023.03.001_bib0225","first-page":"89","article-title":"Drug induced systemic Lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?","volume":"66","author":"Raschi","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2023.03.001_bib0230","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by pembrolizumab: a case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.reumae.2023.03.001_bib0235","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40744-020-00246-z","article-title":"Immune checkpoint inhibitors associated scleroderma-like syndrome: a report of a pembrolizumab induce \u201ceosinophilic fascitis-like\u201d case and review of literature","volume":"7","author":"Salamaliki","year":"2020","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.reumae.2023.03.001_bib0240","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0597-x","article-title":"Recurrent pseudogot after therapy with immune checkpoint inhibitor: a case report with immunoprofiling of synovial fluid at each flare","volume":"7","author":"Kim","year":"2019","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.reumae.2023.03.001_bib0245","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune related adverse events with checkpoint inhibitors affecting the skeleton: a seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.reumae.2023.03.001_bib0250","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2021.07.021","article-title":"Antiphospholipid syndrome induced ischemic stroke following pembrolizumab: a case report and systematic review","volume":"160","author":"Tota","year":"2021","journal-title":"Lung Cancer."},{"key":"10.1016\/j.reumae.2023.03.001_bib0255","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0260","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0265","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy related toxicities, Version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.reumae.2023.03.001_bib0270","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune related adverse events, need for systemic immunosuppression and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0275","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/annonc\/mdw128","article-title":"Safety of the PD1 antibody pembrolizumab in patients with high grade adverse events under ipilimumab treatment","volume":"27","author":"Bender","year":"2016","journal-title":"Ann Oncol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0280","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer clinical practice guideline on immune checkpoint inhibitor related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.reumae.2023.03.001_bib0285","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.41587","article-title":"Expert perspective: immune checkpoint inhibitors and rheumatologic complications","volume":"73","author":"Cappelli","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0290","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel Wahab","year":"2018","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.reumae.2023.03.001_bib0295","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaoncol.2022.2081","article-title":"Association between toxic effects and survival in patients with cancer and autoimmune disease treated with checkpoint inhibitor immunotherapy","volume":"8","author":"Han","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.reumae.2023.03.001_bib0300","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.reuma.2019.03.004","article-title":"Immunotherapy, cancer and rheumatic diseases","volume":"15","author":"N\u00f3voa Medina","year":"2019","journal-title":"Reumatol Clin."}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217357432300028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217357432300028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:03:19Z","timestamp":1761879799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S217357432300028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S217357432300028X"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2023.03.001","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rheumatological adverse events secondary to immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2022.09.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}